TWI370818B - Cocrystal of c-glycoside derivative and l-proline - Google Patents

Cocrystal of c-glycoside derivative and l-proline

Info

Publication number
TWI370818B
TWI370818B TW096111913A TW96111913A TWI370818B TW I370818 B TWI370818 B TW I370818B TW 096111913 A TW096111913 A TW 096111913A TW 96111913 A TW96111913 A TW 96111913A TW I370818 B TWI370818 B TW I370818B
Authority
TW
Taiwan
Prior art keywords
cocrystal
proline
glycoside derivative
glycoside
derivative
Prior art date
Application number
TW096111913A
Other languages
English (en)
Other versions
TW200811152A (en
Inventor
Masakazu Imamura
Keita Nakanishi
Ryota Shiraki
Kenichi Onda
Daisuke Sasuga
Masamichi Yuda
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38563736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI370818(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of TW200811152A publication Critical patent/TW200811152A/zh
Application granted granted Critical
Publication of TWI370818B publication Critical patent/TWI370818B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW096111913A 2006-04-05 2007-04-03 Cocrystal of c-glycoside derivative and l-proline TWI370818B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006103711 2006-04-05

Publications (2)

Publication Number Publication Date
TW200811152A TW200811152A (en) 2008-03-01
TWI370818B true TWI370818B (en) 2012-08-21

Family

ID=38563736

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096111913A TWI370818B (en) 2006-04-05 2007-04-03 Cocrystal of c-glycoside derivative and l-proline

Country Status (15)

Country Link
US (1) US8097592B2 (zh)
EP (1) EP2009010A4 (zh)
JP (1) JP5210154B2 (zh)
KR (2) KR101243039B1 (zh)
CN (1) CN101443328B (zh)
AU (1) AU2007232763B2 (zh)
BR (1) BRPI0710581A2 (zh)
CA (1) CA2649022C (zh)
IL (1) IL194512A0 (zh)
MX (1) MX2008012705A (zh)
NO (1) NO20084659L (zh)
RU (1) RU2408595C2 (zh)
TW (1) TWI370818B (zh)
WO (1) WO2007114475A1 (zh)
ZA (1) ZA200809201B (zh)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309980B (en) * 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US8198464B2 (en) 2006-12-21 2012-06-12 Astellas Pharma Inc. Method for producing C-glycoside derivative and intermediate for synthesis thereof
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
JP5302900B2 (ja) * 2008-01-31 2013-10-02 アステラス製薬株式会社 脂肪性肝疾患の治療用医薬組成物
HUE029970T2 (en) 2008-08-22 2017-04-28 Theracos Sub Llc Method for producing SGLT2 inhibitors
RS52236B (en) * 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
JP4759102B2 (ja) * 2009-10-23 2011-08-31 アステラス製薬株式会社 経口投与用医薬組成物
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2011060256A2 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Bilayer tablet formulations
RU2564901C2 (ru) 2009-11-13 2015-10-10 Бристол-Майерс Сквибб Кампани Композиции метформина с уменьшенной массой
PL2498759T3 (pl) 2009-11-13 2019-03-29 Astrazeneca Ab Formulacje tabletek o natychmiastowym uwalnianiu
WO2011143296A1 (en) 2010-05-11 2011-11-17 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP2014504639A (ja) 2011-02-01 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー アミン化合物を含む医薬製剤
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
PL2697218T3 (pl) 2011-04-13 2016-11-30 Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2
WO2012144592A1 (ja) * 2011-04-22 2012-10-26 アステラス製薬株式会社 固形医薬組成物
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CA2837627A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2013064909A2 (en) * 2011-10-31 2013-05-10 Scinopharm Taiwan, Ltd. Crystalline and non-crystalline forms of sglt2 inhibitors
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
RU2497804C1 (ru) * 2012-05-02 2013-11-10 Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук Сокристаллическая форма 2-гидроксибензамида с 4-аминобензойной кислотой
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2722327A1 (en) * 2012-10-22 2014-04-23 Quantum Genomics Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
CN103910769B (zh) * 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
EP3862003B1 (en) 2013-12-17 2023-10-25 Boehringer Ingelheim Vetmedica GmbH An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
WO2015095703A1 (en) * 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
PL3096765T3 (pl) 2014-01-23 2019-05-31 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt psowatych
MX2016012705A (es) 2014-04-01 2016-12-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales equinos.
KR101613488B1 (ko) 2014-06-18 2016-04-20 (주) 디엔디이 Mice 행사용 초대장 회답 통합관리시스템
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
BR112017003570A2 (pt) 2014-09-25 2017-12-05 Boehringer Ingelheim Vetmedica Gmbh tratamento de combinação de inibidores de sglt2 e agonistas de dopamina para prevenir distúrbios metabólicos em animais equinos
WO2017032799A1 (en) 2015-08-27 2017-03-02 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising sglt-2 inhibitors
EP3349762B1 (en) 2015-09-15 2021-08-25 Laurus Labs Limited Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
CN106924206A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种依格列净口服固体制剂及其制备方法
CA3085331A1 (en) * 2017-12-11 2019-06-20 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
US20190343853A1 (en) * 2018-04-25 2019-11-14 Theracos Sub, Llc Methods of treating hypertension
KR102097250B1 (ko) 2019-11-09 2020-04-03 유니셀랩 주식회사 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
EP4138826A1 (en) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102660615B1 (ko) 2020-10-28 2024-04-26 동방에프티엘(주) 이프라글리플로진의 신규 공결정 및 이의 제조 방법
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
US20240307426A1 (en) 2021-07-28 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Materials and methods for improved phosphotransferases
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
WO2024184293A1 (en) 2023-03-06 2024-09-12 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0600232A2 (en) * 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TWI309980B (en) * 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
CN103819465A (zh) 2003-08-01 2014-05-28 田边三菱制药株式会社 新颖化合物
CA2534664C (en) * 2003-09-04 2012-10-30 Cephalon, Inc. Modafinil compositions
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8198464B2 (en) 2006-12-21 2012-06-12 Astellas Pharma Inc. Method for producing C-glycoside derivative and intermediate for synthesis thereof

Also Published As

Publication number Publication date
BRPI0710581A2 (pt) 2011-08-16
RU2408595C2 (ru) 2011-01-10
ZA200809201B (en) 2009-12-30
KR20090015912A (ko) 2009-02-12
US20090143316A1 (en) 2009-06-04
CN101443328B (zh) 2012-07-25
JP5210154B2 (ja) 2013-06-12
RU2008143362A (ru) 2010-05-10
NO20084659L (no) 2009-01-02
MX2008012705A (es) 2008-10-15
WO2007114475A1 (ja) 2007-10-11
US8097592B2 (en) 2012-01-17
EP2009010A4 (en) 2012-06-13
EP2009010A1 (en) 2008-12-31
CA2649022A1 (en) 2007-10-11
AU2007232763A1 (en) 2007-10-11
TW200811152A (en) 2008-03-01
IL194512A0 (en) 2009-08-03
KR101243039B1 (ko) 2013-03-20
CN101443328A (zh) 2009-05-27
JPWO2007114475A1 (ja) 2009-08-20
AU2007232763B2 (en) 2011-07-28
KR20120025001A (ko) 2012-03-14
CA2649022C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
TWI370818B (en) Cocrystal of c-glycoside derivative and l-proline
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
IL195346A0 (en) Novel heterocyclic compound or salt thereof and intermediate thereof
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
EP2001338A4 (en) FURNITURE
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
HK1129206A1 (zh) 三嗪衍生物的新醫療用途
GB0622472D0 (en) Novel heterocyclic derivatives
ZA200809112B (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL195061A0 (en) Crystalline forms of atorvastatin
EP1986997A4 (en) NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP1934196A4 (en) CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION
EP2068903A4 (en) S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
HUP0500947A2 (en) Composition for treatment of paradontosis
TWM300229U (en) Improvement of lockset device
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees